cas 2970213-45-5|| where to buy 3-(2-bromo-7-oxo-4,5-dihydrothieno[2,3-c]pyridin-6-yl)piperidine-2,6-dione

Produktname:3-(2-bromo-7-oxo-4,5-dihydrothieno[2,3-c]pyridin-6-yl)piperidine-2,6-dione

IUPAC Name:3-{2-bromo-7-oxo-4H,5H,6H,7H-thieno[2,3-c]pyridin-6-yl}piperidine-2,6-dione

: CAS：2970213-45-5; Molekulare Formel：C12H11BrN2O3S; Reinheit：97%

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM1076101-100mg	in stock	ŉĽǵ
CM1076101-250mg	in stock	ưŉĽ
CM1076101-500mg	in stock	ůŉưŉ
CM1076101-1g	in stock	ƓǤưǤ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2970213-45-5 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2970213-45-5; Molekulare Formel:C12H11BrN2O3S; Schmelzpunkt:-; SMILES-Code:BrC1=CC2=C(S1)C(=O)N(CC2)C1CCC(=O)NC1=O; Dichte:

: Katalognummer:CM1076101; Molekulargewicht:343.2; Siedepunkt:; Mdl-Nr.:; Lagerung:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.